Portela 2.5 mg - Solution for injection

Authorised

- Relfovetmab

Product identification

Medicine name:
Portela 2.5 mg - Solution for injection

Active substance:
Relfovetmab

Target species:
Cat

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Relfovetmab

Pharmaceutical form:
Solution for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QN02BG92

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:
Netherlands

Package description:
Packaging:Cardboard box, Package_size:1 vial, Content:1 ml
Packaging:Cardboard box, Package_size:6 vials, Content:1 ml
Packaging:Cardboard box, Package_size:2 vials, Content:1 ml

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - new active substance (Article 8 of Regulation (EU) 2019/6)

Marketing authorisation holder:
Zoetis Belgium

Marketing authorisation date:
27/10/2025

Manufacturing sites for batch release:
Zoetis Belgium

Responsible authority:

European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
27/10/2025

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 4/11/2025
Download

ema-puar-v5890-portela-initial-en.pdf